Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …

Among all the known differences between cancer and normal cells, it is only the genetic
differences that unequivocally distinguish the former from the latter. It is therefore not …

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …

Rational and efficient development of new molecular cancer therapeutics requires
discovery, validation, and implementation of informative biomarkers. Measurement of …

Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …

To assess the effect of age on response and compliance to treatment in patients with chronic
myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA …

Chronic myeloid leukemia (CML) is characterized by a genomic translocation generating a
permanently active BCR-ABL oncogene with a complex pattern of atypically tyrosine …

The monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT)
polymerase chain reaction (PCR) analysis of BCR-ABL transcripts allows early detection of …

Abstract Background: For Philadelphia chromosome positive (Ph+) leukemias (chronic
myelogenous leukemia [CML], acute lymphoblastic leukemia [ALL], and rare other …

Context.—There is ample evidence from the solid tumor literature that synoptic reporting
improves accuracy and completeness of relevant data. No evidence-based guidelines …